Michael Liebowitz, MD: The Mental Health Impact of COVID-19
For many patients suffering from depression or anxiety, the added stress of the pandemic has led to a medication change.
Related Articles
Audrey Chun, MD: Practical Recommendations to Give Older Patients for Exercise, Cognitive Health
In this interview, Chun discussed recommendations for internal medicine physicians to give older adults for slowing aging as well as evidence for statins.
GLP-1 Receptor Agonists Not Linked to Post-Op Respiratory Complications
A retrospective challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.
FDA Approves Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
FDA approves the generic equivalent of Narcan HCI Nasal Spray—naloxone hydrochloride (Naloxone HCI)—for an emergency treatment option for an opioid overdose.
Study Highlights Trends in Atopic Dermatitis Web Search Volume in Europe
This analysis highlighted several trends in search volume regarding eczema, including correlations with weather and climate.
Upadacitinib Superior in Efficacy to Dupilumab for Atopic Dermatitis in Head-to-Head Study
New phase 3b/4 trial data compared both drugs efficacy and safety profiles for eczema patients, looking at adults and adolescents.
Long-term Risankizumab Treatment Outperforms Placebo in PsA
Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.
Thoracic Ultrasound Refines Detection of ILD in Rheumatoid Arthritis
Thoracic ultrasound examination may be applicable as a screening method for interstitial lung disease in patients with RA and respiratory symptoms.
Calliditas Announces Open Label Extension Results for Budesonide (Nefecon) in IgA Nephropathy
Positive topline results showed treatment response consistent with NefIgArd findings, regardless of whether participants had previously been treated with Nefecon or placebo.
Phase 3 Data on Brilaroxazine for Schizophrenia with Larry Ereshefsky, PharmD
In an interview with HCPLive, Larry Ereshefsky, PharmD, discussed the phase 3 RECOVER trial assessing brilaroxazine at 50 mg and 15 mg for acute schziophrenia.
Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors
A recent meta-analysis of more than 60 studies suggests guselkumab and risankizumab had the longest drug survival of IL-17 and IL-23 inhibitors for psoriasis.